Fifty 1 Labs, Inc. Accelerates Growth with New CEO, BioSentry Division Launch and Shareholder Dividend; Company Pursues Strategic Growth Through UAV Partnership and Targeted Acquisitions in Advanced Tech and Wellness
Fifty 1 Labs announces major corporate changes with Michael Lawson appointed as CEO and Chairman, while launching its new BioSentry Division. The division will focus on developing advanced biohazard sensing technology for real-time detection of biological, chemical, and environmental threats.
The company has formed a strategic partnership with UAV Corp to integrate biohazard detection with unmanned aerial vehicles. FITY shareholders will receive UMAV shares as a dividend, with details pending. The company also disclosed that its previously announced acquisition of Genetic Networks was not finalized after due diligence, and Gennaro D'Urso's employment agreement was rescinded.
Key developments include:
- BioSentry's advanced sensor technology utilizing PCR, immunoassays, and spectrometry
- Plans to pursue Department of Defense contracts
- Brandon Spikes continuing as President overseeing sports and wellness division
- Robert Clark remaining on Board of Directors
Fifty 1 Labs annuncia importanti cambiamenti aziendali con la nomina di Michael Lawson a CEO e Presidente, e il lancio della nuova Divisione BioSentry. Questa divisione si concentrerà sullo sviluppo di tecnologie avanzate per il rilevamento in tempo reale di minacce biologiche, chimiche e ambientali.
L'azienda ha stretto una partnership strategica con UAV Corp per integrare il rilevamento di biohazard con veicoli aerei senza pilota. Gli azionisti di FITY riceveranno azioni UMAV come dividendo, con dettagli ancora da definire. Inoltre, è stato comunicato che l'acquisizione precedentemente annunciata di Genetic Networks non è stata completata dopo la due diligence, e l'accordo di lavoro con Gennaro D'Urso è stato annullato.
Sviluppi chiave includono:
- La tecnologia avanzata dei sensori BioSentry che utilizza PCR, immunoassay e spettrometria
- Piani per perseguire contratti con il Dipartimento della Difesa
- Brandon Spikes continuerà come Presidente con responsabilità sulla divisione sport e benessere
- Robert Clark rimane nel Consiglio di Amministrazione
Fifty 1 Labs anuncia importantes cambios corporativos con la designación de Michael Lawson como CEO y Presidente, además del lanzamiento de su nueva División BioSentry. Esta división se enfocará en desarrollar tecnología avanzada para la detección en tiempo real de amenazas biológicas, químicas y ambientales.
La empresa ha formado una alianza estratégica con UAV Corp para integrar la detección de bio-peligros con vehículos aéreos no tripulados. Los accionistas de FITY recibirán acciones de UMAV como dividendo, con detalles pendientes. También se informó que la adquisición previamente anunciada de Genetic Networks no se concretó tras la debida diligencia, y el contrato laboral de Gennaro D'Urso fue rescindido.
Desarrollos clave incluyen:
- Tecnología avanzada de sensores de BioSentry que utiliza PCR, inmunoensayos y espectrometría
- Planes para buscar contratos con el Departamento de Defensa
- Brandon Spikes continuará como Presidente supervisando la división de deportes y bienestar
- Robert Clark permanece en el Consejo de Administración
Fifty 1 Labs는 Michael Lawson을 CEO 겸 회장으로 임명하고 새로운 BioSentry 부서를 출범시키는 주요 기업 변화를 발표했습니다. 이 부서는 생물학적, 화학적, 환경 위협을 실시간으로 감지하는 첨단 생물위험 감지 기술 개발에 집중할 예정입니다.
회사는 UAV Corp와 전략적 파트너십을 맺어 무인 항공기와 생물위험 감지 기술을 통합합니다. FITY 주주들은 배당으로 UMAV 주식을 받게 되며, 세부 사항은 추후 공지됩니다. 또한 Genetic Networks 인수가 실사 과정 후 최종 확정되지 않았으며, Gennaro D'Urso의 고용 계약도 취소되었다고 밝혔습니다.
주요 발전 사항은 다음과 같습니다:
- PCR, 면역측정법, 분광법을 활용한 BioSentry의 첨단 센서 기술
- 국방부 계약 추진 계획
- Brandon Spikes가 스포츠 및 웰니스 부서 총괄 사장직 유지
- Robert Clark이 이사회에 계속 남음
Fifty 1 Labs annonce d'importants changements au sein de l'entreprise avec la nomination de Michael Lawson en tant que CEO et Président, tout en lançant sa nouvelle Division BioSentry. Cette division se concentrera sur le développement de technologies avancées de détection des risques biologiques en temps réel pour identifier les menaces biologiques, chimiques et environnementales.
L'entreprise a établi un partenariat stratégique avec UAV Corp pour intégrer la détection des risques biologiques aux véhicules aériens sans pilote. Les actionnaires de FITY recevront des actions UMAV en dividende, les détails restent à préciser. La société a également révélé que l'acquisition annoncée précédemment de Genetic Networks n'a pas été finalisée après la due diligence, et que le contrat de travail de Gennaro D'Urso a été annulé.
Les développements clés comprennent :
- La technologie avancée des capteurs BioSentry utilisant la PCR, les immuno-essais et la spectrométrie
- Des plans pour poursuivre des contrats avec le Département de la Défense
- Brandon Spikes continue en tant que Président supervisant la division sport et bien-être
- Robert Clark reste au Conseil d'administration
Fifty 1 Labs kündigt bedeutende Unternehmensänderungen an, mit Michael Lawson als neuem CEO und Vorsitzenden, und der Einführung der neuen BioSentry-Abteilung. Diese Abteilung wird sich auf die Entwicklung fortschrittlicher Biohazard-Erkennungstechnologien zur Echtzeitidentifikation biologischer, chemischer und umweltbezogener Gefahren konzentrieren.
Das Unternehmen hat eine strategische Partnerschaft mit UAV Corp geschlossen, um die Biohazard-Erkennung mit unbemannten Luftfahrzeugen zu integrieren. FITY-Aktionäre erhalten UMAV-Aktien als Dividende, Details stehen noch aus. Außerdem wurde bekannt gegeben, dass die zuvor angekündigte Übernahme von Genetic Networks nach der Due Diligence nicht abgeschlossen wurde und der Arbeitsvertrag von Gennaro D'Urso aufgehoben wurde.
Wesentliche Entwicklungen umfassen:
- BioSentrys fortschrittliche Sensortechnologie unter Verwendung von PCR, Immunoassays und Spektrometrie
- Pläne zur Verfolgung von Verträgen mit dem Verteidigungsministerium
- Brandon Spikes bleibt Präsident und leitet die Sport- und Wellness-Abteilung
- Robert Clark bleibt im Vorstand
- New CEO Michael Lawson appointed, bringing leadership stability
- Launch of BioSentry Division with advanced biohazard sensing technology
- Strategic partnership with UAV Corp (UMAV) for drone integration
- Planned shareholder dividend through UMAV shares distribution
- Pursuing DoD contracts for potential multi-million dollar opportunities
- Diversified revenue streams through sports/wellness (51 LLC) and biosecurity divisions
- Failed acquisition of Genetic Networks after due diligence
- Rescinded employment agreement with previously announced executive Gennaro D'Urso
- No immediate revenue from BioSentry technology as still in development phase
- Exact terms and timeline of UMAV share dividend not specified
Company Pursues Strategic Growth Through UAV Partnership and Targeted Acquisitions in Advanced Tech and Wellness
MELBOURNE, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs, Inc. (OTC: FITY), a leader in innovative technology and wellness solutions, is thrilled to announce that Michael Lawson has assumed the roles of Chief Executive Officer and Chairman of the Board, effective immediately. Mr. Lawson will also spearhead the newly established Fifty 1 Labs BioSentry Division, dedicated to advancing a cutting-edge biohazard sensing sensor technology designed to detect and analyze biological, chemical, and environmental threats in real-time.
The Fifty 1 Labs BioSentry Division will develop state-of-the-art biohazard sensing sensors capable of detecting pathogens (e.g., bacteria, viruses, fungi), biological agents (e.g., anthrax, ricin), chemical contaminants (e.g., heavy metals, cyanotoxins), and hazardous materials (e.g., volatile organic compounds, nerve agents). Leveraging advanced techniques such as polymerase chain reaction (PCR), immunoassays, spectrometry, gas chromatography, and ion mobility spectrometry, the sensors offer:
- Real-time monitoring with high sensitivity and specificity for rapid threat response.
- Toxin detection in water sources using electrochemical and optical methods.
- Compact design for integration with unmanned aerial vehicles (UAVs) for aerial surveillance.
- IoT-enabled data analytics with AI-driven hazard prediction and mitigation strategies.
- Environmental resilience for operation in extreme conditions.
The BioSentry technology will empower applications in environmental monitoring (e.g., detecting algae blooms), public health (e.g., identifying airborne pathogens), defense (e.g., chemical weapons detection), and industrial safety (e.g., hazardous material leaks), positioning Fifty 1 Labs as a trailblazer in advanced sensor solutions.
Fifty 1 Labs is also excited to announce a strategic partnership with UAV Corp (OTC: UMAV) to advance UAV-integrated biohazard detection capabilities. As part of this collaboration, Fifty 1 Labs plans to issue a dividend of UMAV shares to FITY shareholders, strengthening alignment between the companies and their investors. Details of the dividend will be shared in the coming months.
Leadership Transition and Shareholder Alignment
It was previously announced that Genetic Networks LLC had been acquired by Fifty 1 Labs, Inc. However, after the 30-day due diligence process, the acquisition was not finalized and the Board of Directors and shareholder majority felt it was in the best interest of the shareholders not to move forward. In connection with this decision, Fifty 1 Labs confirms that Gennaro D'Urso's employment agreement was never signed and the offer of employment was rescinded. The company extends its best wishes to Mr. D'Urso in his future endeavors.
Strategic Focus and Continued Leadership
Fifty 1 Labs will be working to secure multi-million-dollar Department of Defense (DoD) contracts as part of its growth strategy, leveraging the capabilities of its BioSentry technology and UAV integration initiatives. Brandon Spikes will continue in his role as President and Director, overseeing 51 LLC, FITY's sports and wellness division. In addition, Robert Clark will remain with the company as a member of its Board of Directors, providing continued strategic guidance as Fifty 1 Labs advances its mission.
"Michael Lawson's leadership marks an exciting chapter for Fifty 1 Labs as we innovate in biohazard detection and deliver value to our shareholders," said a company spokesperson. "Our partnership with UAV Corp and the launch of the Fifty 1 Labs BioSentry Division, alongside our premium supplement line, underscore our commitment to addressing global safety and wellness challenges with groundbreaking solutions."
For more information, please visit www.fifty1labs.com.
About Fifty 1 Labs, Inc.
Fifty 1 Labs, Inc. (OTC: FITY) is a technology and wellness company focused on developing cutting-edge solutions for public safety, environmental monitoring, industrial applications, and personal health. The Fifty 1 Labs BioSentry Division is advancing a cutting-edge biohazard sensing sensor technology designed to detect and analyze biological, chemical, and environmental threats in real-time. Through its subsidiary, 51 LLC, the company offers a premium line of supplements, including pre-workout formulas, BCAAs, ION+ Electrolyte Formulas, Turmeric Gummies, and Ashwagandha Gummies. With a commitment to innovation and shareholder value, Fifty 1 Labs is dedicated to addressing global challenges through advanced technology and wellness solutions.
Contact: Investor Relations Fifty 1 Labs, Inc.
Email: ir@fifty1labs.com
Phone: +1 877-814-4188
About UAV Corp.
UAV Corp. (OTC: UMAV) is a Wyoming-based innovator in advanced aerial systems, delivering cutting-edge solutions for defense, logistics, and emergency response. With a focus on growth and technological leadership, UAV Corp. is committed to creating shareholder value and pursuing a Nasdaq uplisting.
Contact: Michael Lawson, CEO
Email: mlawson@uavcorp.net
Phone: (877) 425-1066
115 County Road 381, Wewahitchka, FL 32465
www.uavcorp.net
Safe Harbor Statement:
The information provided in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Identifiable by words such as "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions, these statements may also be made in written or oral form in the company's filings with the U.S. Securities and Exchange Commission, OTC Markets, press releases, other written materials, or in oral statements made by its officers, directors, or employees to third parties. There can be no assurance that such statements will prove to be accurate. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Disclosure Statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the company's control. The company does not undertake any obligation to update publicly or to revise any statements in this release, whether as a result of new information, future events, or otherwise.
Wire Service Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
FAQ
What is the new BioSentry Division launched by Fifty 1 Labs (FITY) in April 2025?
How will FITY shareholders benefit from the UAV Corp (UMAV) partnership announced in 2025?
What happened to the Genetic Networks acquisition by Fifty 1 Labs (FITY)?
What are the main applications of FITY's BioSentry sensor technology?
What is Fifty 1 Labs (FITY) strategy for Department of Defense contracts?
